Endocrinol Metab > Volume 37(6); 2022 > Article |
|
Treatment group | Euthyroid | Hypothyroida | Subclinically hyperthyroid |
---|---|---|---|
Methimazole (n=52) | 50 | 2 | 0 |
Radioactive iodine (n=54) | 25 | 25 | 4 |
Variable | Methimazole (n=52) | All |
Radioactive iodine (n=54) |
||||
---|---|---|---|---|---|---|---|
Euthyroid (n=25) | Hypothyroid (n=17) | Relapse (n=12) | |||||
Time to euthyroidism, mo | 4.3±3.1a (2-15) | 11.4±6.1 (3-24) | 12.3±6.3 (3-22) | 9.2±5.2 (3-21) | 13.2±4.6 (9-24) | ||
Percent time spent in | |||||||
Euthyroidism | 95.8±5.7a (78-100) | 72.4±14.8 (50-100) | 82±12 (57-100) | 73±14 (50-90) | 59±10b (50-75) | ||
Overt hypothyroidism | 0 | 2.5±3.3 (0-10) | |||||
Subclinical hypothyroidism | 0.9±0.5 (0-5) | 6.0±9.3 (0-35) | |||||
Overt hyperthyroidism | 0 | 1.7±4.2 (0-20) | |||||
Subclinical hyperthyroidism | 3.3±6.0 (0-22) | 17.4±12.8 (0-50) |
No. | Age, yra | Sex | Follow-up time, mo | Time to Euthyroidism, mo |
Percentage of time spent in |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Euthyroidism | Hypothyroidism (subclinical) | Hypothyroidism (overt) | Hyperthyroidism (subclinical) | Hyperthyroidism (overt) | Final thyroid status | ||||||
MMI group | |||||||||||
1 | 70 | F | 125 | 3 | 100 | 0 | 0 | 0 | 0 | Eu | |
2 | 72 | F | 118 | 3 | 100 | 0 | 0 | 0 | 0 | Eu | |
3 | 66 | F | 116 | 2 | 95 | 5 | 0 | 0 | 0 | Eu | |
4 | 67 | F | 109 | 5 | 100 | 0 | 0 | 0 | 0 | Eu | |
5 | 68 | F | 131 | 5 | 95 | 0 | 0 | 5 | 0 | Eu | |
6 | 67 | F | 133 | 3 | 95 | 0 | 0 | 5 | 0 | Eu | |
7 | 70 | M | 130 | 3 | 95 | 0 | 0 | 5 | 0 | Eu | |
8 | 70 | F | 121 | 3 | 95 | 5 | 0 | 0 | 0 | Eu | |
9 | 71 | M | 122 | 4 | 100 | 0 | 0 | 0 | 0 | Eu | |
10 | 67 | F | 116 | 2 | 95 | 0 | 0 | 5 | 0 | Eu | |
11 | 72 | F | 115 | 4 | 90 | 5 | 0 | 5 | 0 | Eu | |
12 | 67 | F | 124 | 3 | 100 | 0 | 0 | 0 | 0 | Eu | |
Mean±SD | 122±7 | 3.3±1.0b | 97±3b | ||||||||
RAI group | |||||||||||
13 | 68 | F | 135 | 11 | 100 | 0 | 0 | 0 | 0 | Eu | |
14 | 72 | F | 127 | 4 | 97 | 0 | 0 | 3 | 0 | Eu | |
15 | 69 | M | 129 | 30 | 75 | 0 | 0 | 25 | 0 | Sc.hyper | |
16 | 72 | F | 152 | 25 | 79 | 0 | 0 | 21 | 0 | Eu | |
17 | 71 | M | 120 | 5 | 90 | 5 | 0 | 5 | 0 | Sc.hyper | |
18 | 66 | F | 148 | 4 | 50 | 35 | 10 | 5 | 0 | O.hypo | |
19 | 69 | F | 129 | 7 | 80 | 5 | 5 | 10 | 0 | O.hypo | |
20 | 70 | F | 136 | 19 | 58 | 28 | 10 | 20 | 0 | O.hypo | |
21 | 67 | F | 116 | 9 | 75 | 25 | 5 | 5 | 0 | O.hypo | |
22 | 70 | F | 128 | 14 | 75 | 15 | 5 | 5 | 0 | O.hypo | |
23 | 71 | M | 119 | 24 | 50 | 0 | 0 | 40 | 10 | Eu/Rec (4) | |
24 | 70 | M | 137 | 20 | 80 | 0 | 0 | 40 | 10 | Eu/Rec (3) | |
25 | 67 | F | 131 | 9 | 50 | 0 | 0 | 40 | 10 | O hypo/Rec (2) | |
Mean±SD | 131±11 | 13.9±8.8 | 72±17 |
Patients no. 13 to 22 received only one dose of RAI. Patients no. 23, 24, and 25 had 4, 3, and 2 relapses of hyperthyroidism, respectively; their final thyroid state was euthyroidism in No. 23 and 24 and hypothyroidism in No. 25.
MMI, methimazole; Eu, euthyroidism; SD, standard deviation; RAI, radioactive iodine; Sc.hyper, subclinical hyperthyroidism; O.hypo, overt hypothyroidism; Rec, recurrence (number of relapses).
Fereidoun Azizi
https://orcid.org/0000-0002-6470-2517
Navid Saadat
https://orcid.org/0000-0001-7118-647X
Hengameh Abdi
https://orcid.org/0000-0002-6850-0090
Atieh Amouzegar
https://orcid.org/0000-0001-9433-9408